|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1260 - 0.1375|
|52 Week Range||0.0940 - 0.6045|
|Beta (5Y Monthly)||1.69|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
* Plenitude Trial initiated * Tetra completes clinical study assessing the metabolism profile of cannabinoids in humans * Achieved development of ARDS-003 sterile injectable nano-emulsion for human useOTTAWA, ON / ACCESSWIRE / November 16, 2020 / Tetra Bio-Pharma Inc.
* Initial Drug Indication Targets COVID-19 Related Survival Benefits * Cost-Saving Including When Used With a Remdesivir™ Standard of Care * Expanded Post-Survival Indications (Reduce the Risk of Fibrosis and Multi-Organ Dysfunctions) * Tetra Estimates Potential Revenues From Royalties on Net Sales, Milestone and Upfront Payments of Over $500 Million USD by 2026OTTAWA, ON / ACCESSWIRE / November 4, 2020 / Tetra Bio-Pharma Inc.
OTTAWA, ON, Nov. 2, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc.